Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | FASN | P49327 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420672 | 0.83 | HTT (0.53) | EGLN1HPGDEGLN2HTTSMN1; SMN2 | |
| SCHEMBL13162882 | 0.81 | CNR1 (0.42) | EGLN1FASNLRRK2RAB9A | |
| SCHEMBL28840065 | 0.80 | EGLN1 (0.48) | EGLN1POLBHTTSMN1; SMN2LRRK2 | |
| SCHEMBL28839773 | 0.78 | ALDH1A1 (0.51) | EGLN1HPGDPOLBSMN1; SMN2LRRK2 | |
| SCHEMBL14280004 | 0.78 | ALOX15 (0.50) | HPGDPOLBHTTSMN1; SMN2MAPK1 | |
| SCHEMBL30641945 | 0.77 | LRRK2 (0.51) | EGLN1FASNCDK1POLBLRRK2 | |
| SCHEMBL20787533 | 0.77 | LRRK2 (0.51) | EGLN1FASNCDK1POLBLRRK2 | |
| SCHEMBL289565 | 0.77 | LRRK2 (0.45) | HPGDPOLBSMN1; SMN2LRRK2 | |
| SCHEMBL13161984 | 0.77 | ESRRB (0.49) | HPGDPOLBHTTSMN1; SMN2MAPK1 | |
| SCHEMBL1420715 | 0.77 | HTT (0.56) | HPGDHTTSMN1; SMN2MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | EGLN1 3941/4885TRPA1 59/4885FASN 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.